Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Christian Hinrichs
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05639972CT.gov E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | — | Recruiting | — | — | — |
NCT05686226CT.gov E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adenosquamous Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| e7 tcr-t cells (this asset) | Christian Hinrichs | P2 | B · 58 |
| Carboplatin | Pfizer | P3 | B |
| Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer | Pfizer | P3 | CCC |
| Tsc-204-C0702 | TScan Therapeutics, Inc. | P1 | CC |
| Tsc-204-A0101 | TScan Therapeutics, Inc. | P1 | CC |
| Tsc-203-A0201 | TScan Therapeutics, Inc. | P1 | CC |
| Tsc-200-A0201 | TScan Therapeutics, Inc. | P1 | CC |
| Tsc-204-A0201 | TScan Therapeutics, Inc. | P1 | CC |
| Tsc-202-A0201 | TScan Therapeutics, Inc. | P1 | CC |
+1 more in the Adenosquamous Carcinoma cohort
Other indications for e7 tcr-t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cervical Carcinoma | — | P2 | B · 60 |
| Oropharynx Cancer | — | P2 | B · 60 |
| Vulva Cancer | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinPfizerB
- Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, DimerPfizerCCC
- Tsc-204-C0702TScan Therapeutics, Inc.CC
- Tsc-204-A0101TScan Therapeutics, Inc.CC
- Tsc-203-A0201TScan Therapeutics, Inc.CC
Citation
Floatz Terminal. e7 tcr-t cells in Adenosquamous Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/e7-tcr-t-cells-adenosquamous-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →